Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy
Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, 2-arm, parallel group study of up to 274 evaluable
patients designed to evaluate the safety and efficacy of the histone deacetylase 6 (HDAC6)
inhibitor ricolinostat for painful DPN.